Researchers at UMass Chan Medical School have developed a small interfering RNA (siRNA) technology that is stable enough for inhalation into the lungs, where it can potentially treat diseases as diverse as asthma, pulmonary fibrosis, and viral infections such as COVID-19. siRNA is not typically stable enough to survive for long in the lungs, but the researchers chemically modified the constituent nucleotides to stabilize the molecules and help them to evade immune destruction. The technology is designed to silence genes that are crucial in disease processes.
A recent study in Nature Medicine, entitled “An automated histological classification system for precision diagnostics of kidney allografts,” has showcased the efforts of a group of researchers who have developed an automated system that can diagnose kidney transplant rejection.
A variety of disparate factors can affect the chances that a transplant will be rejected. At present, clinicians have to manually consider these complex data when making decisions about transplant patients, which can lead to a high level of misdiagnosis and patient morbidity.